AMGEN WILL REPORT EARNINGS 10 DAYS EARLY.Byline: Jim Finkle Bloomberg Bloomberg A major global provider of 24-hour financial news and information including real-time and historic price data, financials data, trading news and analyst coverage, as well as general news and sports. News Amgen Inc., the world's largest biotechnology company, said it will report second-quarter earnings Monday Monday: see week. , about 10 days ahead of schedule, citing ``unusual'' trading in its stock in the past week. Amgen shares have soared 14 percent this week in heavier-than-usual trading amid expectations that the company's results will exceed forecasts, buoyed by strong sales of its top-selling drug, the anemia anemia (ənē`mēə), condition in which the concentration of hemoglobin in the circulating blood is below normal. Such a condition is caused by a deficient number of erythrocytes (red blood cells), an abnormally low level of hemoglobin treatment Epogen E·po·gen A trademark for the drug epoetin alfa. epoetin alfa Epogen, Eprex (CA) (UK), Procrit Pharmacologic class: Recombinant human erythropoietin Therapeutic class: . ``Given the recent unusual trading in the stock, senior management just thought it would be best to report sooner, rather than later,'' said Amgen spokesman David Kaye David V. Hope (born 14 October 1964), known professionaly as David Kaye, is a Canadian actor who is better known and revered for his work as a voice actor. Career . Thousand Oaks-based Amgen is expected to earn 46 cents a share in the second quarter, the average forecast of analysts surveyed by First Call Corp. Kaye Kaye , Danny 1913-1987. American entertainer known for his comedic roles in such motion pictures as Wonder Man (1944) and The Secret Life of Walter Mitty (1946). declined to comment on the company's performance during the quarter. Amgen shares rose $3.6975 to $69.3125 on Friday. The stock fell as low as $52.125 last month as some analysts advised clients to sell it because they interpreted comments from the company as signals it would miss second-quarter earnings estimates. Amgen traded at a record high of $81.375 on April 6. The stock has risen over the past two weeks as other analysts determined that their colleagues misinterpreted the signals from Amgen and urged investors to buy shares before it reported results. ``There was confusion as to what the earnings were,'' said Charles Engel, an AmeriCal Securities analyst with a buy recommendation on Amgen. CAPTION(S): Chart CHART: AMGEN SURGE Amgen shares are up 20 percent in 2 weeks. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion